Focus: LFB is a mid-cap biotech specializing in plasma-derived drug products for rare hematologic and infectious diseases, headquartered in Paris with 1,001–5,000 employees. The company operates an active pipeline of 8 clinical programs spanning Phase 2–4 development.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Hot — 395 jobs added in 30d
Net +333 (395 new, 62 removed). Aggressive expansion phase.
LFB is a solid mid-stage biotech opportunity for manufacturing, quality, and supply-chain professionals seeking rare-disease expertise, but limited financial transparency and early-stage innovation warrant due diligence.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for LFB
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from LFB's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Acute Respiratory Distress Syndrome Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Veru, Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeu - Barchart.com
Acute Respiratory Distress Syndrome Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Veru, Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeu Barchart.com
Acute Respiratory Distress Syndrome Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Veru, Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeu - Barchart.com
Acute Respiratory Distress Syndrome Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Veru, Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeu Barchart.com
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
LASSBio-1986 as a Multifunctional Antidiabetic Lead: SGLT1/2 Docking, Redox-Inflammatory Modulation and Metabolic Benefits in C57BL/6 Mice.
Health-related quality of life in adults with von Willebrand disease: results of the French real-life Willebrand study on health-related quality of life.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo